KLK3 and prostate cancer: An ongoing clinical trial, NCT02771769, is examining the utility of ctDNA in men with elevated PSA undergoing prostate biopsy to determine if copy number instability correlates with prostate cancer diagnosis and may reshape the landscape of prostate cancer screening (http://clinicaltrials.gov).